AZNAstraZeneca PLC
What is the market doing?
No clear lean: insiders net buying, but in a downtrend (−12% vs 200-day).
In a downtrend, below its 50- and 200-day averages. Price is −12% vs its 200-day average.
Insiders were net buyers over the 90 days ending Oct 8, 2026.
A token position, settled Sep 15, 2026, a few days of normal trading to cover. Down 28% since the previous count, unchanged over three months.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How AZN is trading
AstraZeneca PLC is +5.4% over the past year while the S&P 500 is +18%: 13 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −12%
vs 200-day average · a clear downtrend
- RSI (14)
- 32
RSI (14) · neutral
- Below its 52-week high
- 24%
Below its 52-week high
Details›
- Last close2026-10-09
- $159.19
- 1 monthS&P 500 +2.7%
- −0.27%
- 1 yearS&P 500 +18%
- +5.4%
- 5 yearsS&P 500 +88%
- +57%
- vs 50-day average$162.24
- −1.9%
- 52-week high
- $208.62
- 52-week low
- $145.54
- Annualised volatility
- 26%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-09
- −$2.2M
| Year | Return |
|---|---|
| 2026 (year to date) | −13% |
| 2025 | +43% |
| 2024 | −0.62% |
| 2023 | +1.4% |
| 2022 | +19% |
| 2021 | +20% |
| 2020 | +3.1% |
| 2019 | +36% |
| 2018 | +14% |
| 2017 | +33% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 4 of 10 | +0.01% |
| Feb | 10 | 6 of 10 | +4.2% |
| Mar | 10 | 7 of 10 | +2.6% |
| Apr | 10 | 6 of 10 | +2.6% |
| May | 10 | 7 of 10 | +3.2% |
| Jun | 10 | 3 of 10 | −0.00% |
| Jul | 11 | 8 of 11 | +1.7% |
| Aug | 11 | 6 of 11 | +1.00% |
| Sep | 11 | 4 of 11 | −0.99% |
| Oct | 11 | 5 of 11 | −0.97% |
| Nov | 10 | 5 of 10 | +0.79% |
| Dec | 10 | 5 of 10 | +0.90% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, General
Ranks #5 of 7 by RyuScore